H
igher infliximab (IFX) serum concentrations have been associated with improved clinical and endoscopic outcomes in patients with Crohn's disease (CD) and ulcerative colitis (UC). 1, 2 Serum trough level-based dosing of IFX resulted in lower rates of disease relapse compared with conventional (clinically based) dosing in patients with inflammatory bowel disease (IBD) in remission in a recent Belgian study that also showed that more patients remained in remission when the IFX serum concentration at trough was kept above 3 mg/mL. 3 Individualized algorithm-based therapy was also more cost-effective than routine IFX dose escalation in patients with CD. 4 Adjusting the IFX dose based on serum concentrations, also described as therapeutic drug monitoring, has currently been incorporated in most therapeutic algorithms and has become part of clinical practice in many medical centers worldwide. 5, 6 Several factors have been suggested to influence the pharmacokinetics (PK) of IFX in patients with IBD. 5, 7 The development of antibodies to IFX (ATIs) was found to reduce serum IFX concentrations and negatively impact response. 8 However, ATI status is usually reported as a dichotomous parameter (positive or negative). To what extent ATI titers influence IFX PK has not extensively been investigated to date. Recent evidence suggests that patients with insufficient exposure to IFX might be predisposed to develop ATIs. 9 Concomitant immunosuppressive therapy reduces ATI formation and improves the PK of IFX. 10 In addition, post hoc PK analysis of 2 clinical trials in UC revealed that serum IFX concentrations were negatively correlated with serum albumin levels. 11 Finally, higher serum C-reactive protein (CRP) levels reflecting more severe disease activity have been correlated with lower serum IFX concentrations. 1, 9 Notably, these factors have mainly been derived from clinical trials with strict inclusion or exclusion criteria, often excluding patients with IBD with complicated and severe disease and observe patients over a limited period. 12 Other studies have used computer modeling to identify predictive determinants of IFX PK; nonetheless, reports of the assessment of long-term clinical data from daily practice are scarce.
We aimed to study the real-life PK of IFX in a large cohort of patients with IBD to identify patient, disease, and treatment characteristics that influence IFX PK. In addition, we aimed to investigate the association between IFX exposure and ATI development and between ATI titers and IFX concentrations.
METHODS

Study Design
In this study, we identified all patients with IBD in whom serum IFX concentrations had been measured at the Academic 
Outcome Measures
Medical charts of all patients were reviewed in detail for patient, disease, and treatment characteristics. Patients' characteristics that were registered included sex, age, length and body weight, and smoking status. For disease characteristics, information about type, duration, location, and behavior of disease (Montreal Classification) was collected. In addition, IFX treatment data were recorded, specifically dosing regimen (exact dose and frequency) and the use of concomitant immunomodulators. Finally, selected laboratory values (hemoglobin, thrombocytes, leukocytes, erythrocyte sedimentation rate, serum CRP, albumin, alanine transaminase, and aspartate transaminase) were also entered in the database when measured during IFX treatment.
The timing of all measurements relative to the last IFX infusion was registered. The indication for IFX concentration and ATI measurement was generally suspicion of loss of response, but IFX concentrations were also measured in the patients in clinical remission to screen for potential dose reduction. Serum IFX concentrations and ATI titers were measured using a validated enzyme-linked immunosorbent assay and antigen-binding test (radioimmunoassay; Sanquin Laboratories, Amsterdam, The Netherlands). [13] [14] [15] Lower limits of quantification were as follows: 0.003 mg/mL for IFX serum concentration and 12 AU/mL for ATI titer. This assay is "drug sensitive," meaning that ATIs cannot be measured in the presence of more than 1 mg/mL of circulating drug.
Pharmacokinetic and Statistical Analysis
IFX concentrations and ATI data were analyzed by nonlinear mixed-effects modeling using NONMEM 7.3 software (ICON Development Solutions Inc., Dublin, Ireland). Concentrations were described using a 2-compartment PK model with first-order elimination. 16 A log-transform both sides approach was used to improve model stability and also to ensure the model would not produce negative concentrations. The stochastic approximation expectation method was implemented, and the M3 method was used to allow observations below the limit of assay to contribute to the likelihood. 17 Model building was conducted using standard approaches. 18 First, a PK model was built. Covariates were then evaluated graphically, and those showing trends or those known to influence IFX PK were evaluated individually with NONMEM and accepted at P , 0.01 using the likelihood ratio test. 19 All influential covariates were then combined into a full model. Covariates were retained on backward elimination at P , 0.001 (multivariate analysis).
Once the PK model was stable, the PK parameters were fixed and the ATI data were evaluated as continuous variable using a semiphysiologic 2-part model where low IFX concentrations were used as a trigger to form ATIs. In the first part of the 2-part model, the probability of developing ATIs was described using a "time-to-event" model which allowed exploration of patient factors contributing to ATIs and the time-to-event component used the time above the "trigger concentration" (which was estimated as an IFX trough level of 3 mg/mL) to contribute to increasing probability of ATI formation. Once the ATIs had formed, the model produced individually estimated absolute ATI titers, which were then fed back to the PK model to increase IFX clearance.
Finally, all models were evaluated using both nonparametric unstratified bootstrap and visual predictive check (VPC). 20, 21 For the VPCs, the final model was used to simulate multiple replicates (n ¼ 1000) of the original database. From the simulated data, percentiles were calculated by simulation replicate, and the "grand percentiles" and associated confidence intervals were determined over all simulated replicates. The same percentiles were determined from the observed data. In a VPC, the modelsimulated percentiles and observed percentiles should generally be in agreement, and the observed data should be contained within the 2.5th to 97.5th percentiles of the simulated data. In addition, basic goodness of fit plots and other model performance metrics were assessed for all models. 22 
RESULTS
A total of 1000 distinct IFX concentrations and 760 ATI titers from 333 patients with IBD were collected in this study. Data from one patient were excluded because of insufficient dosing information; 2 PK observations and 4 ATI titers were omitted because of high conditional weighted residuals (a diagnostic tool to test for model misspecification). This resulted in the final inclusion of serum IFX concentration data from 332 patients with IBD (253 CD and 79 UC), with 997 IFX observations (median 2 observations, range 1-18) and 756 ATI titers (median 2 observations, range 1-16) ( Table 1 ). For CD, 55/ 253 patients had ileal, 80/253 patients had colonic, and 118/253 had ileocolonic disease. For UC, 6/79 patients were classified as proctitis, 30/79 patients had left-sided colitis, and 43/79 pancolitis.
Two hundred sixty-four of 332 (80%) patients received IFX as their first anti-TNF treatment, and 144/332 (43%) were receiving concomitant immunomodulation, at a mean (SD) IFX dose of 5.47 6 1.33 mg/kg. Seventy-three of the 144 patients received immunomodulators intermittently or at varying doses, mainly because of intolerance or incompliance. IFX measurements were mostly collected during maintenance therapy (731/ 997, 73%), but also induction measurements were available (266/997, 27%). Most measurements (804/997, 81%) were trough concentrations (collected just before an infusion); however, in some patients, also "pre-trough/mid-infusion" measurements were available specifically during induction phase. IFX was undetectable in 125/997 (13%) samples. ATIs were detected in 75/332 (23%) patients, resulting in unmeasurable serum IFX concentrations in 83% of the samples taken concomitantly. ATI titer was superior to ATIs as a dichotomous parameter to predict IFX clearance. ATI titers higher than 30 AU/mL (n ¼ 76) were consistently associated with unmeasurable IFX concentrations in all samples, in contrast to low, but measurable, IFX concentrations in samples with ATI titers #30 AU/mL. Thus, deduced from this data, an ATI titer of .30 AU/mL was found as a threshold for undetectable IFX concentrations. IFX PK was well described using a 2-compartment model with linear clearance. The mean (interindividual variability) values for clearance and central and peripheral volumes of distribution were 0.359 L/d (38%), 4.72 L (69%), and 2.4 L (72%), respectively. The factors which influenced the PK of IFX were similar for CD and UC (Table 2A) . The parameters for the probability of developing ATIs (Table 2B ) could be clearly identified and were well estimated. The time window during which IFX concentrations had fallen below the target trough of 3 mg/mL was the most predictive factor of developing ATIs according to the model. Other trough concentrations were tested, but 3 mg/mL was found to be most predictive of ATI formation. This risk was cumulative and exponential, meaning the more often this was observed, the higher the likelihood that a patient would develop ATIs. Serum albumin and body weight had only small contributions to the hazard after this first factor was accounted for and were thus not retained in the model. The parameters for the formation of ATIs (Table 2C) were highly variable, reflecting large interindividual differences in the formation of ATIs. The ATI titers, high body weight, and low serum albumin were identified as covariates independently (P , 0.001) affecting clearance (Fig. 1 Patients who were previously exposed to anti-TNF had a slightly, but significantly, higher IFX clearance than patients who received IFX as their first biologic agent (0.36 versus 0.34, independent association). Other patient, disease, or treatment characteristics such as sex, age, body length, smoking status, disease duration, location or behavior, use of immunomodulators, hemoglobin, thrombocytes, leukocytes, erythrocyte sedimentation rate, serum CRP, alanine FIGURE 2. VPCs depicting the predicted IFX concentrations over time based on the factors that were identified by the model based on the observations in this study. The open blue symbols are the observed IFX PK data; the solid red line is the median of the observed IFX PK data; the dashed red lines are the lower 2.5th and upper 97.5th percentiles of the observed IFX PK data; the solid black line is the median of the simulated IFX PK data; the black dashed lines are the lower 25th and upper 97.5th percentiles of the simulated IFX PK data; and the shaded gray area is the confidence interval of the simulated percentiles. CI, confidence interval.
transaminsase, and aspartate transaminase were not associated with changes in clearance.
VPCs for both patients with CD and UC showed that the model based on the above mentioned factors could accurately predict IFX serum concentrations for both diseases (Fig. 2) . In this model, serum albumin reduces the intraindividual variability on clearance by 28.6%, body weight by 28.2%, ATIs by 9%, and previous anti-TNF exposure by 2% (P , 0.001).
Preliminary graphical evaluation indicated that the risk of developing ATIs was associated with low serum albumin, high body weight, and previous anti-TNF exposure; all of these factors were associated with higher IFX clearance. These suggest that patients with a faster clearance are at higher risk of ATI formation than patients with slower clearance, possibly owing to the fact that such patients are likely to have periods with no circulating IFX. In addition, the risk of ATIs was associated with the time during which IFX concentrations were below 3 mg/mL (Fig. 3) . However in Figure 3D , the lowest quartiles of IFX exposure were not associated with higher risk of ATIs-this seemed to be due to loss of clinical response; hence, patients were taken off IFX before ATIs were detected. A time-to-event model was developed to relate IFX concentrations to the probability of ATIs. This model identified a time dependence in the hazard of ATIs, with the highest risk occurring early in therapy and diminishing over time. The time dependence did not seem to be attributable to patients discontinuing therapy. Importantly, this function found that the amount of time over a dose interval where IFX concentrations were $3 mg/mL predicted a reduced hazard of ATIs for patients with more than 98.9% of their samples above the critical concentration of 3 mg/mL. Thus, looking at continuous IFX exposure as the proportion of time that IFX concentration is above the "target concentration" of $ 3 mg/mL, the model suggests that as soon as concentrations drop below 3 mg/mL, the risk of developing ATIs increases dramatically and time to development of ATIs diminishes substantially. The association between patients having low IFX concentrations and the probability of ATIs showed that when patients had longer time intervals below the identified target concentration, the probability of ATIs increased, as shown graphically in Figure 4 .
The VPC plot for ATIs showed that the model was able to predict the occurrence of ATIs. (Fig. 5) The VPC for ATIs showed some early appearance of ATIs that was not well predicted by the model; however, later appearance of ATIs was well predicted. Figure 6 shows the simulated survival curves and associated confidence intervals of the probability of not developing ATIs for patients with IFX concentrations $3 mg/mL over less than 98.9% of the dose interval (panel A), versus more than 98.9% of a dose interval (panel B). The time dependence for development of ATIs is clearly demonstrated in panel A, which also shows that despite falling below the target trough, some patients will still not develop ATIs.
DISCUSSION
In this study, we demonstrated that insufficient exposure to IFX, reflected by the time during which IFX concentrations fell below a trough level of 3 mg/mL during a dose interval, was the most predictive factor of developing ATIs. Thus, concentrations falling below the "trigger concentration" of 3 mg/mL contribute to the probability of clinically relevant immunogenicity. If this trigger is reached repeatedly or during a prolonged period of time, ATI formation was highly probable. This finding supports therapeutic drug monitoring to ensure appropriate coverage and to reduce the risk of ATI formation and consequently treatment failure.
As is shown in Figure 6 , the percentage of patients developing ATIs without monitoring and proactive dose adjustments would be expected to result in approximately 25% of patients failing therapy due to ATIs within the first 2 years of therapy, whereas appropriate dose adjustment would potentially lower this to approximately 5%. Owing to the time dependence in the probability of ATIs, ensuring that trough concentrations do not fall below 3 mg/ mL is, therefore, particularly important early in therapy.
In this study, the titer of ATIs was a substantially better predictor of IFX clearance than just their presence as a binary parameter (i.e., ATI positive or negative). We also observed that all patients with ATI titer .30 AU/mL had no detectable IFX concentrations, indicating that ATI titer had a major clinical significance. ATI responses have been reported to appear either in the transient or persistent form. 23, 24 The clinical meaning of (transient) antidrug antibodies has been a matter of debate in previous studies. 25, 26 In this study, we used the first measurable titer for the model to identify the factors that influence the time to formation of ATIs, which is therefore unlikely to be affected by the transient appearance of these antibodies. Furthermore, we confirmed in this real-life clinical cohort, with long-term use of IFX, that ATIs, high body weight, and low serum albumin levels are consistently associated with increased IFX clearance from the serum leading to a significantly shorter half-life. A model, based on the PK factors that were identified in this study, as shown by VPCs for both CD and UC ( Fig. 2A-C) could accurately forecast serum IFX concentrations consistent with the observed data. As a consequence, such a model seems to be useful for personalized dosing of IFX.
Anti-TNF naive patients exhibited slightly lower clearance than previously exposed patients. This difference may be due to more refractory (and thus severe) disease in previously exposed patients. Furthermore, previously exposed patients may have a higher predisposition to develop antidrug antibodies.
A recent study also revealed that serum albumin, body weight, and ATIs led to increased clearance of IFX. 27 In addition, a PK model for dose optimization was also assessed in a retrospective study in 42 patients with IBD; however, this study included only patients who were responding to IFX with detectable drug levels. 28 In this report, body weight was not detected as a factor affecting clearance, but male gender was found to be associated with a 35% higher clearance than female gender. In our study, the average weight of the male patients was 79.14 kg with an associated average clearance of 0.44 L/d, whereas the average weight of the female patients was 66.5 kg and their clearance was 0.355 L/d (19.3% lower than that of males). Therefore, the suggested effect of sex on clearance is likely to be a reflection of the independent effect of body weight. Also, as opposed to previous reports, we did not find a difference in the PK between patients with UC and CD. It seems important, though, to recognize that the above mentioned studies included patients with IBD in the maintenance phase of treatment and that PK during induction may differ. The current report, however, is based on data from a large and heterogeneous cohort, with multiple IFX measurements per patient and taking into account IFX measurements that were below the limit of assay quantification. This large number of patients allowed for accurate analysis of patient, disease, and treatment factors that influenced clearance. Moreover, simultaneous modeling of IFX and ATIs (as a continuous function) allowed to determine the IFX concentrations needed to reduce the likelihood of developing ATIs, which is attractive for clinicians
The clearance of IFX in this study was much higher than that previously reported in patients with rheumatoid arthritis and ankylosing spondylitis, but comparable to reports in IBD, which may be a reflection of a relatively higher inflammatory burden, with larger amounts of TNF to be neutralized in IBD. 27, [29] [30] [31] In addition, this increased clearance may be reflective of immunoglobulin degradation by metalloproteinases or protein-losing enteropathy which is unlikely to occur in patients with rheumatoid arthritis and ankylosing spondylitis. 32 This high inflammatory load with potential loss of intestinal epithelial integrity may lead to rapid consumption of therapeutic antibodies in the vascular and intestinal compartments. 33 FIGURE 5. VPCs depicting the predicted ATI titer over time based on the factors that were identified by the model based on the observations in this study. The open blue symbols are the observed data; the solid black line is the median of the simulated ATI titers; the black dashed lines are the lower 25th and upper 97.5th percentiles of the simulated ATI titers; and the shaded gray area is the confidence interval of the simulated percentiles for ATIs. Because the number of patients with multiple nonzero ATI values was low, the intervals for the observed data were omitted from this figure.
A pharmacokinetic study in patients with rheumatoid arthritis identified preinfusion CRP and concomitant use of methotrexate as factors influencing the PK of IFX. 30 Our study could not reproduce these finding in patients with IBD. Elevation of serum CRP is absent in large proportion of patients with mild-to-moderately active IBD. 34 Moreover, CRP levels change rapidly during IFX treatment, particularly during induction therapy, whereby the timing of measurement (before/after treatment) can influence the CRP levels considerably. Therefore, serum CRP could not be evaluated in detail as an independent covariate in this study.
The (nonprotocolized) use of concomitant immunomodulators was intermittent in many of our patients (73 of 144 patients on immunomodulators did not receive these drugs continuously). In particular, during the first year of thiopurine use, patients had to reduce their thiopurine dose or even discontinue because of side effects, intolerance, or toxicity. After initiation or discontinuation of thiopurines and methotrexate, clearance did not change instantly because the gradual drug interacting effect of immunomodulatory agents on IFX PK may take some time. The use of continuous concomitant immunomodulators was nevertheless associated with a decrease in clearance over time.
Whether ATI formation is the cause or consequence of low IFX drug levels remains uncertain with the drug sensitive assay used in this study. Possibly, antibodies that are "technically unmeasurable" with assays that cannot detect antibodies in the presence of high circulating drug concentrations may also affect IFX clearance and could, thereby, have preceded the antidrug antibodies that we measured. So far, however, only detectable ATIs have proven clinical relevance. From our study, it can be deduced that low IFX concentrations (,3 mg/mL) are probably the first signal that can be detected with the current drug-sensitive assay that will precede the development of detectable and clinically relevant ATIs.
Limitations of this study include the retrospective design which was associated with missing laboratory data and hampered the response assessment in some patients and restricted the association with clinical outcome. In addition, as mentioned previously, we did not use a drug-tolerant assay, which probably FIGURE 6. Simulated survival curves for patients without antidrug antibodies versus time based on whether IFX concentrations stayed above the target trough (3 mg/mL) for equal or more than 98.9% of time or fell below this target. The solid lines are the median simulated time without developing ATIs; the dashed lines are the approximate 90% confidence intervals. A, the expected survival time when troughs are allowed to fall below 3 mg/mL for equal or more than 98.9% of time; B, the expected survival time when troughs are maintained at 3 mg/mL or higher. PTGT3, the proportion of time the IFX concentration is .3 mg/mL. P (No ADA), proportion of patients without anti-drug antibodies.
led to a delay in the detection of ATIs. However, extensive patient and treatment and disease characteristics were available in all patients.
The indication for the measurement of (trough) IFX serum concentrations and ATI measurements were generally suspicion of loss of response; however, in some patients, induction levels were assessed as well. These variable indications resulted in a heterogeneous population. However, PK analysis can correct for the time to previous infusion, making the data even more robust than analyses just based on trough levels.
In conclusion, ATI titer was a better predictor of IFX clearance than ATI as a dichotomous parameter. Clearance was higher in previously exposed compared with anti-TNF-naïve patients. Patients whose concentrations fell below the "trigger concentration" long enough had a high probability of developing ATIs, which was more acute during early therapy. Routine therapeutic drug monitoring and dose adjustment to sustain sufficient exposure to IFX may play a critical role in reducing the likelihood of ATIs. As suggested earlier by our group, IFX antibodies can develop (and be detected) as early as day 18 after the initiation of treatment, so this phenomenon is certainly also clinically relevant during induction treatment.
Incorporating these PK factors in model-guided dosing may, therefore, improve outcomes compared with current standard dosing. Dashboard systems, which can help to make therapeutic decisions regarding dosing, provide a promising tool in the tailored management of patients with IBD. 35 Future studies, such as the ongoing PRECISION study (Clinical.Trials.gov identifier: NCT02453776), will determine whether individualized dosing of IFX based on PK factors, such as body weight, ATI titers, serum albumin, and CRP, will improve the prediction of IFX levels and result in higher likelihood of sustained clinical remission and cost reduction compared with conventional IFX dosing.
